Alnylam Pharmaceuticals, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:ALNY) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 4.21 B4.57 B4.85 B4.97 B5.13 B Total liabilities 4.1 B4.32 B4.62 B4.18 B4.05 B Total equity 115.44 M250.59 M233.89 M789.18 M1.08 B Total liabilities & shareholders' equities 4.21 B4.57 B4.85 B4.97 B5.13 B Total debt 1.03 B1.03 B1.04 B1.01 B1.01 B Net debt -1.61 B-1.83 B-1.68 B-1.9 B-2 B

News

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200

Strength in Chipmakers Boosts Stock Indexes

Alnylam: Unexpected Rival Trial Failure Improves Core TTR Franchise Outlook (ALNY)

Stocks Climb on Strength in Chipmakers

AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study

Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump

Stock Market Today: S&P 500 Gains Traction Amid Iran News; Arm, Dell Lead Upside (Live Coverage)

Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders - Slideshow (NASDAQ:ALNY) 2026-06-25

Regeneron's Applications for gMG Drug Accepted by FDA and EMA

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?